New Delhi: Drug firm Roche has recently announced the launch of the new VENTANA HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast and gastric cancer. HER2, human epidermal growth factor receptor 2 is an important biomarker found in breast and gastric cancers. Its detection and inhibition can help to more effectively manage these aggressive cancers.
The VENTANA HER2 Dual ISH DNA Probe Cocktail assay is designed to be completed within the same day, providing clinicians with the ability to get results back quicker than the most common methods of confirmatory testing for HER2. Results can be read using light microscopy, eliminating the need for a specialized fluorescence microscope.
The VENTANA HER2 Dual ISH DNA Probe Cocktail assay aids in identifying breast and gastric cancer patients eligible for the targeted Roche drug Herceptin (trastuzumab), providing fast results with widely available laboratory instruments.
This approval supports Roche’s personalized healthcare strategy to provide treatment to patients who can benefit most from a specific medicine.
Commenting on the launch, Michael Heuer, CEO Roche Diagnostics said, “The new VENTANA HER2 Dual ISH assay advances Roche’s commitment to personalized healthcare by delivering critical information on treatment options for breast and gastric cancer patients faster.”
“Quick results are crucial in the fight against cancer, and every additional day that a clinician and a patient must wait for test results is a day too long,” Heuer added.
This assay is currently being launched in Europe, the Middle East and Africa, as well as Latin America and the Asia Pacific. It will be submitted to the U.S. Food and Drug Administration for approval.